ENLV
Enlivex Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.21
+1.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.21
From 52W high−98.86%
Volume584559.00
Market cap$4.13M
P/E (TTM)0.0x
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.21
From 52W high
−98.86%
Volume
584559.00
Market cap
$4.13M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
0.0x
RSI (14)
11.9
MomentumView details →
1D Return
+1.17%
YTD Return
−98.12%
SummaryUpdated Jun 1, 2026
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) is an Israeli clinical-stage biotechnology company founded in 2005 and headquartered in Nes Ziona, Israel. The company went public in 2014 and specializes in developing innovative cell-based immunotherapies focused on macrophage reprogramming. Enlivex operates as a pure-play research and development company with no current revenue, dedicating its resources to advancing its lead therapeutic candidate through clinical trials for life-threatening conditions including sepsis and solid tumors.
Similar companies
Latest newsMore news →
Enlivex announced a cost-reduction plan effective immediately to reduce cash burn and focus resources on its Phase 2b Allocetra trial for knee osteoarthritis.15h agoEnlivex Ltd. terminated its previously announced financing that was payable in RAIN tokens.28d agoEnlivex, a Nasdaq-listed biotech company, is seeking shareholder approval to authorize up to $800 million in financing, potentially increasing share count by up to 951%, with proceeds primarily used to acquire the RAIN crypto token for treasury purposes.80d ago